Daily Stock Analysis, AIMT, Aimmune Therapeutics Inc, priceseries

Aimmune Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
24.17
Close
25.00
High
25.06
Low
24.17
Previous Close
24.21
Daily Price Gain
0.79
YTD High
26.81
YTD High Date
Sep 16, 2019
YTD Low
16.95
YTD Low Date
Jul 11, 2019
YTD Price Change
0.66
YTD Gain
2.69%
52 Week High
36.12
52 Week High Date
Nov 7, 2018
52 Week Low
16.95
52 Week Low Date
Jul 11, 2019
52 Week Price Change
-3.29
52 Week Gain
-11.62%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 20. 2017
18.56
Jul 26. 2017
21.24
25 Trading Days
14.44%
Link
LONG
Nov 8. 2017
30.94
Dec 4. 2017
36.23
17 Trading Days
17.09%
Link
LONG
Jan 30. 2019
22.86
Feb 13. 2019
24.07
10 Trading Days
5.30%
Link
Company Information
Stock Symbol
AIMT
Exchange
NasdaqGS
Company URL
http://www.aimmune.com
Company Phone
(650) 614-5220
CEO
Stephen George Dilly
Headquarters
California
Business Address
8000 MARINA BOULEVARD, SUITE 300, BRISBANE, CA 94005-1884
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001631650
About

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy (CODIT) system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.

Description

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. The company was founded in 2011 and is headquartered in Brisbane, California.